Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Decreases By 44.5%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 21,094 shares, a decrease of 44.5% from the July 15th total of 38,037 shares. Based on an average trading volume of 10,788 shares, the short-interest ratio is currently 2.0 days. Approximately 0.4% of the company’s shares are short sold.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC acquired a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent quarter. 2.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ATHE shares. Zacks Research raised Alterity Therapeutics to a “hold” rating in a research note on Wednesday, June 17th. UBS Group set a $12.00 price objective on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Craig Hallum set a $2.00 target price on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. LADENBURG THALM/SH SH began coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th. They set a “buy” rating and a $10.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Alterity Therapeutics Stock Performance

Alterity Therapeutics stock traded down $0.15 during midday trading on Monday, reaching $4.64. 26,863 shares of the stock traded hands, compared to its average volume of 27,452. The company has a 50-day simple moving average of $4.82 and a two-hundred day simple moving average of $4.16. Alterity Therapeutics has a 12-month low of $2.66 and a 12-month high of $5.89.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.